Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines
Authors:
- 1 June 1997
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 15 (2) , 109-114
Abstract
Approximately 70-80% of patients with metastatic testicular cancer will become disease free with cisplatin-based chemotherapy and most of these patients will be longterm survivors. Despite these...Keywords
This publication has 30 references indexed in Scilit:
- Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatinNature, 1995
- Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancerJournal of Cancer Research and Clinical Oncology, 1994
- Feasibility of High-Dose Platinum Delivery With Combined Carboplatin and OxaliplatinJNCI: Journal of the National Cancer Institute, 1994
- Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rateEuropean Journal of Cancer, 1993
- A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancerCancer, 1992
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI: Journal of the National Cancer Institute, 1990
- Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexesChemico-Biological Interactions, 1989
- Cell lines of human germinal cancerInternational Journal of Andrology, 1987
- Comparative antitumour activity of cisplatin and two new cisplatin‐analogues JM8 and JM9 in human testicular carcinoma xenograftsInternational Journal of Andrology, 1987
- A human embryonal—yolk sac carcinoma model system in athymic miceCancer, 1985